Found 20 matching trials
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
PHASE2To study the minimal residual disease (MRD) clearance rate of olverembatini...
Location
Multiple Locations
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
PHASE3ALLTogether collects the experience of previously successful treatment of i...
Location
L'hôpital Universitaire des enfants Reine Fabiola (Huderf)
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
PHASE2In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (...
Location
Institute of Hematology & Blood Diseases Hospital
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
PHASE2This prospective, randomized, multicenter, open-label Phase 2 study is desi...
Location
St. Anna Kinderspital
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
PHASE2B cell acute lymphoblastic leukemia (B-ALL)/Lymphoblastic lymphoma (LBL) is...
Location
The First Affiliated Hospital, College of Medicine, Zhejiang University
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
PHASE2As part of postremission consolidative therapy, the decision to proceed wit...
Location
The First Affiliated Hospital of Soochow University
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
PHASE3The IntReALL BCP 2020 study aims to review recent developments and findings...
Location
St. Anna Kinderspital GmbH
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NAThis is an open-label, prospective clinical cohort study evaluating the eff...
Location
Blood Diseases Hospital
Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL
PHASE2The aim of the present EWALL-INO study is to confirm very promising results...
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
PHASE2This trial is a non-blinded, single-center, open-label, single-arm clinical...
Location
The First Affiliated Hospital of Soochow University